View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 22, 2021updated 12 Jul 2022 11:18am

Health2047 to enhance clinical trials with spin out of portfolio company

The American Medical Association (AMA) subsidiary Health2047 has spun out portfolio company SiteBridge Research in an effort to improve clinical trial access for small and community physician practices.

The American Medical Association (AMA) subsidiary Health2047 has spun out portfolio company SiteBridge Research in an effort to improve clinical trial access for small and community physician practices.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Through its Trial-In-A-Box platform, SiteBridge gives more access to clinical trials by permitting a broader set of physicians and their patients to take part in research.

The company aims to enable researchers to obtain more targeted data for optimising treatments across a broader patient population by creating a clinical trial network of independent, small practice physicians.

Health2047 CEO Lawrence Cohen said: “We’re excited by SiteBridge Research’s mission to democratise clinical trials by opening access and removing barriers to different parts of the clinical trial ecosystem.

“This involves enabling trials to occur at point-of-care vs traditional large academic institutions.”

SiteBridge’s Trial-In-A-Box platform provides access to clinical research training, resources and support covering the initial feasibility and site start-up until the full study delivery and close out.

It also facilitates research through the application of best-of-breed technology, processes and functional expertise.

The company has seed funding in place and plans to build out a national network to support the next generation of clinical research.

SiteBridge Research CEO Chris Komelasky said: “As health systems vow to improve health outcomes by tackling social determinants and inequities, it’s critical to ensure clinical trials represent the broadest possible patient set.

“Our platform facilitates the participation of smaller physician practices in trials, so research studies can have more representative patient populations for the intended applications of the drugs being tested and create more realistic risk/benefit profiles for new treatments. It puts the focus of research on the trusted relationship between a physician and patient.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena